MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is⦠read more
Healthcare
Biotechnology
1 years
USD
Exclusive to Premium users
$14.15
Price+1.07%
$0.15
$63.976m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$3.769b
-
1y CAGR-
3y CAGR-
5y CAGR-$2.775b
-
1y CAGR-
3y CAGR-
5y CAGR-$2.87
-
1y CAGR-
3y CAGR-
5y CAGR-$25.189m
$2.484m
Assets$27.674m
Liabilities$5.506m
Debt221.6%
-0.5x
Debt to EBITDA-$1.347b
-
1y CAGR-
3y CAGR-
5y CAGR